PTC Therapeutics (PTCT) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of PTC Therapeutics (NASDAQ: PTCT) in the last few weeks:

• 8/13/2026 – PTC Therapeutics had its price target raised by Wells Fargo & Company from $106.00 to $109.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – PTC Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/1/2026 – PTC Therapeutics was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 7/31/2026 – PTC Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/31/2026 – PTC Therapeutics had its price target raised by Morgan Stanley from $93.00 to $104.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – PTC Therapeutics had its price target raised by Wells Fargo & Company from $93.00 to $106.00. They now have an “overweight” rating on the stock.
• 7/20/2026 – PTC Therapeutics had its price target lowered by Wells Fargo & Company from $95.00 to $93.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – PTC Therapeutics had its price target raised by Cantor Fitzgerald from $124.00 to $130.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – PTC Therapeutics had its price target raised by Royal Bank Of Canada from $82.00 to $85.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – PTC Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In other PTC Therapeutics news, Director Mary L. Smith sold 15,834 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $90.00, for a total value of $1,425,060.00. Following the completion of the transaction, the director directly owned 21,813 shares in the company, valued at approximately $1,963,170. This represents a 42.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Christine Marie Utter sold 19,686 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $75.56, for a total transaction of $1,487,474.16. Following the transaction, the chief accounting officer directly owned 70,199 shares of the company’s stock, valued at $5,304,236.44. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 192,842 shares of company stock worth $15,857,035 over the last quarter. 5.30% of the stock is currently owned by corporate insiders.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.